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PCASE2
PHARMACOECONOMIC APPLICATIONS IN FORMULARY
MANAGEMENT:A CASE STUDY OF CETUXIMAB AT A MAJOR
ACADEMIC CANCER CENTER
Miller LA, Lal LS,Arbuckle R
University of Texas—MD Anderson Cancer Center, Houston,TX,
USA
Organization: University of Texas—MD Anderson Cancer
Center (MDACC), Department of Drug Use Policy and
Pharmacoeconomics.
Problem or Issue Addressed: The costs for drugs in cancer treat-
ment continue to increase, especially with the addition of mono-
clonal antibodies and other targeted therapies to standard cancer
treatment regimens. As part of our Formulary Management
System (FMS) we conducted and presented a pre and post-
formulary addition budget impact economic analysis of cetux-
imab in combination with standard chemotherapy for metastatic
colorectal cancer (MCRC).
Goals: The purpose of this project was to demonstrate a process
incorporating budget impact considerations into the Pharmacy
and Therapeutics (P&T) Committee decision process for addi-
tion of new products in the institutional Formulary. A pre-
approval economic model (annual budget impact) for cetuximab
was developed, and was presented to the P&T Committee in
April 2004. In October 2007, a post-approval economic analysis
was conducted to assess the actual annual budget impact of
cetuximab and compare it to the pre-approval economic model.
Outcomes items used in the decision: The following data was
collected: the number of patients; the dose amount; the number
of doses; the number of cycles; the purchase cost, the charge
amount; and the reimbursement amount. The institutional
annual budget impact analysis was done using direct medical
costs, in 2007 United States Dollars.
Implementation Strategy: A pre-approval model was built based
on the FDA approved indication of third-line treatment of
MCRC. Assumptions regarding cetuximab’s use included: dose
estimate/m2, number of doses per cycle per patient, median
number of cycles per patient, and direct medical cost per dose
patient. These data were based on information from published
clinical trials, clinical use estimates and published cost data.
Annual budget impact for the expected MD Anderson popula-
tion of 125 MCRC patients was calculated to be $6,728,000.
This model, along with a clinical monograph, was presented to
the P&T Committee in April 2004 at the vote for cetuximab’s
inclusion onto the institutional Formulary. Subsequently, cetux-
imab was added to the formulary as an add-on drug for meta-
static colorectal cancer patients with two prior therapies, and
with the recommendation that physicians use discretion for use
outside the FDA-indication.
Results: During the time between the pre-and post approval,
Cetuximab was FDA-approved for second-line treatment of
MCRC (February 2004). It was also FDA-approved for head and
neck (H&N) cancer in March 2006. For post-approval analysis,
we reviewed the use in all patients (excluding investigational)
receiving cetuximab at MDACC from June 2006 to May 2007.
During this time period, we had a total of 233 patients on
cetuximab. Of these, 114 (49%) were MCRC patients who had
prior therapies, 83 (36%) were head and neck patients with prior
treatments, and 36 (15%) patients received cetuximab for non
FDA-approved indications. We also reviewed charges and reim-
bursement data collected for the drug from June 2006 to Decem-
ber 2006. For the duration of the study period, we had a positive
margin and our reimbursement to charge ratio for MCRC was
58%, the overall reimbursement to charge ratio for cetuximab
was 56%. Actual annual budget impact was $4,854,230. Based
on this analysis, there were some differences between the model
assumptions and our ﬁndings from actual data. Our model had
predicted 100% usage for the FDA approved indication of third-
line MCRC treatment in an estimated patient population of
estimated125 patients versus 114 actual patients. Overall, actual
data collected showed that we had more than expected number
of patients on cetuximab; we had additional usage for the new
FDA indication where none was previously estimated, and 15%
use in non-approved indications. Also, our original model
assumed a total of 8 cycles of cetuximab therapy per patient,
whereas actual average number of cycles per patient was between
4 and 5. We did not have data to determine whether patients
obtained other cycles of therapy from other providers outside of
the institution.
Lessons Learned: Annual budget impact analysis helped estimate
the cost to the institution for adding cetuximab to the formulary.
Performing an annual budget impact evaluation before addition
of a drug to an institution’s formulary, and comparing it with the
annual budget impact after a few years of the drug being on the
formulary, is an essential process in determining the best use of
expensive resources. We also learnt the importance of including
non-FDA usage in our initial model. Future studies will focus on
calculating the estimated cost-effectiveness of therapies for the
institution’s patient population. This would take into account the
cost of treatment and patients’ outcomes; important in allocating
resources in this era of rising costs.
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USING IN-HOUSE STRATEGIESTO OVERCOME
INCONSISTENCIES BETWEEN EXPENDITURES
AND BUDGETING
Oren M, Schwartzberg E, Ben-Moshe A, Haspel J
Hillel Yaffe Medical Center, Hadera, Israel
Organization: The Hillel—Yaffe Medical Center, a 410 bed, sec-
ondary acute care, teaching hospital, owned by the Israeli
government.
Problem or Issue Addressed: The constant increase in health-care
costs owing to technology advances accompanied by annual
price rise and the lack of an adequate external, government
funding lead the Hillel—Yaffe Medical Center management, to
implement policies for reducing expenditure while maintaining
the quality of care. Consequently, during 2002–2007 two inter-
vention strategies were developed and implemented to solve this
dilemma. The issues targeted and selected were laboratory orga-
nization and institutional tests ordering and drug use process.
Goals: Constraining or decreasing laboratory and pharmacy
budgets while maintaining quality of medical care and introduc-
ing new technologies.
Outcomes items used in the decision: Measures used in the deci-
sion process, its monitoring and analysis were cumulative follow
up budgetary and epidemiological data including: total labora-
tory and pharmacy budgets, Daily Deﬁned Doses (DDD), stan-
dardized average daily and length of stay, standardized patient
medication expenditures, laboratory test ordering utilization
rate, average length of stay and overall mortality and
re-hospitalization rate.
Implementation Strategy: Two ﬁelds of high expenditure produc-
tion ﬂoors (laboratories and pharmacy), accounting for 25% of
the purchasing budget were identiﬁed. A prospective drug and
laboratory test utilization evaluation was conducted to proﬁle
consumption, ordering and prescribing behavior patterns. The
results were formulated into two intervention programs (IPs):
laboratory organization and institutional test ordering (LOTO)
and drug use process (DUP).
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